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Patient and disease characteristics
Case No 1 2 3 4 5 6 7
Age 21 45 4 42 46 12 29
Diagnosis CML-CP AML JMML AML CML -BC AML SAA
Conditioning
regimen
FLU-MEL Flu-Busulfan Flu-Bu-Mel FLA+Ara-C+Ida+Mel Flu-Mel Flu-Mel-Ara-c-ATG Flu-CY
Risk factor High Ferritin Haplo-HSCT High Ferritin,
MUD HSCT
High Ferritin
VOD on day 11 11 12 14 14 14 16
Maximal Bilirubin 3.8 5 1.2 1.4 3.2 1.34 3.1
Weight gain (%) 5 22 10 7.5 5 3 13
Bearman score 10 10 20 16 12 11 16
DF Dose mg/kg/d 5 7 7 5 10 10 10
Duration 6 12 10 6 8 8 12
Resolution by D+17 D+28 D+21 D+20 D+22 D+10 D+24
Organ
dysfunctioon
hepatic
encephalopathy
Oxygen
desaturation
renal failure,
hepatic encephalopathy,
Oxygen desaturation
Oxygen
desaturation
renal dysfunction,
hepatic encephalopathy,
oxygen desaturation
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S191patients received DF in doses ranging from 5 mg /kg/d to 10
mg/kg/d in two divided doses for median of 8 days (range 6
to12 days). Six patients received intravenous DF while 1
patient received oral DF. All patients had complete resolution
of VOD by day +22 post transplant (range day + 17 to day
+28). No dose response relationship was observed between
DF dose and time to resolution of VOD. None developed any
side effects of DF.
Conclusion: A lower dose of DF is effective and safe in treat-
ment of moderate VOD. This is especially relevant in a limited
resource setting, however needs prospective evaluation.
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Background: Following hematopoietic stem cell trans-
plantation (HSCT), the probability that acquired protective
immunity is lost over time is signiﬁcant. Therefore, a sys-
tematic reimmunization is important to re-establish appro-
priate immunity and to decrease the risk of vaccine
preventable infectious diseases with their related morbidity
and mortality. The aim of this study is to investigate whether
the recommendations for vaccination were followed in our
hospital and to which extent of conformity they were used.
Methodology: A 2-year retrospective survey, including adult
allogeneic HSCT patients, (transplanted) at the Ghent Uni-
versity Hospital, Belgium, who were at least 3 months post
transplant. Administration of the ﬁrst dose of conjugated
polysaccharide vaccine against Pneumococci was studied.
Results: Data on vaccination schedules of 50 allogeneic
transplantations were collected. Of these, 34 patients (68,0%)
were eligible for recommended vaccinations. Patients were
vaccinated on-schedule (i.e. time-frame between HSCT and
vaccination as recommended in the hospital guideline) in
76,5% (26/34). Postponed vaccination with a medical indi-
cationwas observed in 8,8% (3/34) of patients. Of them, 66,7%
(2/3) were postponed because of infection and 33,3% (1/3)
because of signiﬁcant thrombocytopenia.
Postponed vaccination without a medical excuse was
observed in a minority of the patients, i.e. 11,8% (4/34), with
either ‘no medical reason’ in 75,0% (3/4) or nonadherence in
25,0% of patients (1/4). Postponed vaccination with initialmedical indication but then followed by non-medical reason
was observed in 2,9% (1/34) of patients. Vaccination data
were not available for 32,0% (16/50) of patients. The reasons
were death before start of vaccination in 75,0% (12/16), graft
failure in 12,5% (2/16) and lack of information in 12,5% (2/16)
of patients.
Conclusion: The results emphasize the need for close follow-
up of post-transplant patients in our hospital. This is
conﬁrmed by satisfactory concordance between the hospital
recommendation and vaccination of HSCT patients. Health-
care providers play a crucial role by effectively and appro-
priately following the vaccination schedules. Moreover,
literature data demonstrate that actively involving the pa-
tient in the follow-up (e.g. providing them with their vacci-
nation schedule) results in improved follow-up. The role of a
personalized electronic alert systemwill be explored in near
future. In addition, the appropriate follow-up of out-patient
vaccination, 1 year after HSCT, will be studied.
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Foscarnet (FOS) remains the primary antiviral option in the
setting of intolerance of and/or resistance to ganciclovir (GCV)
and other inhibitors of viral kinase. However, FOS-associated
nephrotoxicity often limits it utility. Because this nephrotox-
icity can be attenuated by substantially increasing the infusion
time and ensuring adequate hydration, we report a successful
approach to the administration of FOS as a continuous infu-
sion (CI) in both the inpatient and outpatient settings. The
decision regarding administering FOS as a CI was solely at the
discretion of the treating team with most common reasons
cited as attenuation of nephrotoxicity, management of ﬂuid
balance, and facilitation of outpatient care.
Results: Data regarding both groups is summarized in Table
1. Throughout administration, total daily dose was adjusted
per recommendations based on creatinine clearance and
adjusted ideal body weight with an additional liter of
hydration daily. Median duration of treatment was 23 days
(4-123d). 22 of the 25 treatment courses (23 patients)
resulted in successful resolution of the disease process;
